幽门螺杆菌会引起顽固感染，并导致多种胃部疾病，如消化性溃疡、慢性萎缩性胃炎和胃癌。尽管基于抗生素的方法已广泛用于对抗幽门螺杆菌，但抗生素耐药性等一些挑战正在日益严重。因此，需要更简单但更有效的策略。在这篇综述中，以易于理解的形式提供了功能化和非功能化微/纳米生物材料以及幽门螺杆菌抑制给药途径的基本信息。随后，全面讨论了一些有前景的生物平台的体外和体内研究，包括金属基生物材料、生物聚合物、小分子糖和抑制幽门螺杆菌的疫苗。功能化或非功能化微/纳米生物材料装载有抗H.幽门螺杆菌药物可以表现出有效的杀菌活性，对宿主胃肠道微生物群没有/轻微的负面影响。然而，这一说法需要用硬数据来证实，例如抗幽门螺杆菌生物制药参数的评估。幽门螺杆菌系统以及根除幽门螺杆菌前后宿主胃/肠道微生物群中细菌属多样性/丰度的测量。

Helicobacter pylori causes stubborn infections and leads to a variety of stomach disorders, such as peptic ulcer, chronic atrophic gastritis, and gastric cancer. Although antibiotic-based approaches have been widely used against H. pylori, some challenges such as antibiotic resistance are increasing in severity. Therefore, simpler but more effective strategies are needed.In this review, basic information on functionalized and non-functionalized micro/nano biomaterials and routes of administration for H. pylori inhibition are provided in an easy-to-understand format. Afterward, in vitro and in vivo studies of some promising bio-platforms including metal-based biomaterials, biopolymers, small-molecule saccharides, and vaccines for H. pylori inhibition are discussed in a holistic manner.Functionalized or non-functionalized micro/nano biomaterials loaded with anti-H. pylori agents can show efficient bactericidal activity with no/slight negative influence on the host gastrointestinal microbiota. However, this claim needs to be substantiated with hard data such as assessment of the biopharmaceutical parameters of anti-H. pylori systems and the measurement of diversity/abundance of bacterial genera in the host gastric/gut microbiota before and after H. pylori eradication.